D
Daniel Haggstrom
Researcher at Carolinas Healthcare System
Publications - 17
Citations - 2259
Daniel Haggstrom is an academic researcher from Carolinas Healthcare System. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 6, co-authored 13 publications receiving 1895 citations.
Papers
More filters
Journal ArticleDOI
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne,James Chih-Hsin Yang,Dong Wan Kim,David Planchard,Yuichiro Ohe,Suresh S. Ramalingam,Myung-Ju Ahn,Sang We Kim,Wu Chou Su,Leora Horn,Daniel Haggstrom,Enriqueta Felip,Joo Hang Kim,Paul Frewer,Mireille Cantarini,Kathryn H. Brown,Paul A. Dickinson,Serban Ghiorghiu,Malcolm R Ranson +18 more
TL;DR: AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors.
Journal ArticleDOI
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
James Chih-Hsin Yang,Myung-Ju Ahn,Dong Wan Kim,Suresh S. Ramalingam,Lecia V. Sequist,Wu Chou Su,Sang We Kim,Joo Hang Kim,David Planchard,Enriqueta Felip,Fiona H Blackhall,Daniel Haggstrom,Kiyotaka Yoh,Silvia Novello,Kathryn A. Gold,Tomonori Hirashima,Chia-Chi Lin,Helen Mann,Mireille Cantarini,Serban Ghiorghiu,Pasi A. Jänne +20 more
TL;DR: In patients with EGFRm T790M advanced NSCLC who progress after EGFR-TKI treatment, osimertinib provides a high ORR, encouraging PFS, and durable response, and this article reports the results from the phase II extension component.
Journal ArticleDOI
Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Eugene R Ahn,Pam K. Mangat,Elizabeth Garrett-Mayer,Susan Halabi,Elie G. Dib,Daniel Haggstrom,Kathryn B. Alguire,Carmen Julia Calfa,Timothy L. Cannon,Pamela A. Crilley,Anu G. Gaba,Alissa S. Marr,Ashish Sangal,Ramya Thota,Kaitlyn R. Antonelli,Samiha Islam,Andrew L. Rygiel,Suanna S. Bruinooge,Richard L. Schilsky +18 more
TL;DR: Palbociclib monotherapy demonstrated evidence of modest antitumor activity in heavily pretreated patients with NSCLC with CDKN2A alterations, and additional investigation is necessary to confirm efficacy and utility of palbokiclib in this population.
Journal ArticleDOI
449pdupdated safety and efficacy from a phase i study of azd9291 in patients (pts) with egfr-tki-resistant non-small cell lung cancer (nsclc)
J.C.-H. Yang,Dong Wook Kim,David Planchard,Yuichiro Ohe,S.S. Ramalingam,M-J. Ahn,S-W. Kim,W. Su,Leora Horn,Daniel Haggstrom,Enriqueta Felip,Jai Keun Kim,Paul Frewer,Mireille Cantarini,Serban Ghiorghiu,Malcolm R Ranson,Pasi A. Jänne +16 more
TL;DR: AZD9291 has been well tolerated at all dose levels tested and clinical activity has been shown in pts with centrally confirmed EGFR T790M+ NSCLC, with durable responses of >6 months.
Journal ArticleDOI
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.
Corey J. Langer,Edward S. Kim,Eric C. Anderson,Robert M. Jotte,Manuel Modiano,Daniel Haggstrom,Matei P. Socoteanu,David Smith,Christopher Dakhil,Kartik Konduri,Tymara Berry,Teng J. Ong,Alexandra Sanford,Katayoun I. Amiri,Jonathan W. Goldman,Jared Weiss,Abound. + Investigators +16 more
TL;DR: The findings support the results of prior subset analyses on the safety and efficacy of first-line nab-paclitaxel/carboplatin in elderly patients with advanced NSCLC and significantly improved PFS and ORR but did not significantly reduce the percentage of grade ≥ 2 PN or grade’s3 myelosuppression.